Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes | Zendy

William J. Archibald | Zendy; Kari G. Rabe | Zendy; Brian Kabat | Zendy; Joerg Herrmann | Zendy; Wei Ding | Zendy; Neil E. Kay | Zendy; Saad S. Kenderian | Zendy; Eli Muchtar | Zendy; José F. Leis | Zendy; Yucai Wang | Zendy; Asher ChananKhan | Zendy; Susan M. Schwager | Zendy; Amber B. Koehler | Zendy; Amie Fonder | Zendy; Susan L. Slager | Zendy; Tait D. Shanafelt | Zendy; Timothy G. Call | Zendy; Sameer A. Parikh | Zendy

Open Access

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

Author(s) -

William J. Archibald,

Kari G. Rabe,

Brian Kabat,

Joerg Herrmann,

Wei Ding,

Neil E. Kay,

Saad S. Kenderian,

Eli Muchtar,

José F. Leis,

Yucai Wang,

Asher ChananKhan,

Susan M. Schwager,

Amber B. Koehler,

Amie Fonder,

Susan L. Slager,

Tait D. Shanafelt,

Timothy G. Call,

Sameer A. Parikh

Publication year - 2020

Publication title -

annals of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.079

H-Index - 80

eISSN - 1432-0584

pISSN - 0939-5555

DOI - 10.1007/s00277-020-04094-3

Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , hazard ratio , atrial fibrillation , hematology , oncology , retrospective cohort study , adverse effect , proportional hazards model , heart failure , leukemia , confidence interval

Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research